Solasia Pharma K.K. Logo

Solasia Pharma K.K.

In-licenses and commercializes oncology treatments and supportive care products in Asia.

4597 | T

Overview

Corporate Details

ISIN(s):
JP3436500007
LEI:
Country:
Japan
Address:
港区芝公園二丁目11番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Solasia Pharma K.K. is a specialty pharmaceutical company focused on developing and commercializing innovative oncology products to address unmet medical needs in Japan and other Asian countries. The company's business model centers on in-licensing promising drug candidates and medical devices, primarily from the US and Europe. Its portfolio includes approved therapies for cancer treatment, such as Peripheral T-Cell Lymphoma, and supportive care solutions for managing treatment side effects like chemotherapy-induced nausea and vomiting (CINV) and oral mucositis. Solasia's development pipeline targets conditions including colorectal cancer and chemotherapy-induced peripheral neuropathy. The company leverages its small, expert team for quick and flexible decision-making to efficiently bring new treatments to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-13 08:42
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 228.0 KB
2025-03-31 08:49
Registration Form
訂正有価証券届出書(組込方式)
Japanese 147.2 KB
2025-03-31 08:43
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-03-26 07:30
Registration Form
訂正有価証券届出書(組込方式)
Japanese 181.4 KB
2025-03-26 07:21
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 22.7 KB
2025-03-26 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-03-26 07:19
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.1 MB
2025-03-24 07:37
Registration Form
有価証券届出書(組込方式)
Japanese 263.8 KB
2025-03-10 07:31
Regulatory News Service
臨時報告書
Japanese 19.5 KB
2024-08-14 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-14 08:42
Interim Report
半期報告書-第17期(2024/01/01-2024/12/31)
Japanese 238.4 KB
2024-05-15 08:42
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-15 08:40
Quarterly Report
四半期報告書-第17期第1四半期(2024/01/01-2024/03/31)
Japanese 219.9 KB
2024-03-26 07:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB

Automate Your Workflow. Get a real-time feed of all Solasia Pharma K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Solasia Pharma K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Solasia Pharma K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.